Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
暂无分享,去创建一个
Jean-Pierre Gillet | Sudhir Varma | Anil K Sood | Ben Davidson | Michael M Gottesman | M. Gottesman | S. Varma | A. Sood | B. Rueda | A. Calcagno | S. Ambudkar | B. Davidson | R. Padmanabhan | J. Gillet | M. Marino | L. Green | M. Vora | C. Patel | Josiah N. Orina | T. Eliseeva | V. Singal | R. Ganapathi | Suresh V Ambudkar | Ram Ganapathi | Anna Maria Calcagno | Miguel Marino | Lisa J Green | Meena I Vora | Chirayu Patel | Josiah N Orina | Tatiana A Eliseeva | Vineet Singal | Raji Padmanabhan | Bo R Rueda
[1] F. de Longueville,et al. Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes , 2004, Cancer Research.
[2] M. Mendiola,et al. Molecular characterization of ovarian cancer by gene-expression profiling. , 2010, Gynecologic oncology.
[3] J N Weinstein,et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.
[4] M. Gottesman,et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. , 2011, Molecular pharmaceutics.
[5] N. Cheong,et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration , 2008, Leukemia.
[6] Bin Wang,et al. Systematic Evaluation of Three microRNA Profiling Platforms: Microarray, Beads Array, and Quantitative Real-Time PCR Array , 2011, PloS one.
[7] F. de Longueville,et al. ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia , 2006, Clinical Cancer Research.
[8] R. Koch,et al. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug , 2009, Haematologica.
[9] P B Laub,et al. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.
[10] L. Wessels,et al. Do predictive signatures really predict response to cancer chemotherapy? , 2010, Cell cycle.
[11] H Okamura,et al. Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability , 2005, British Journal of Cancer.
[12] D. Botstein,et al. A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.
[13] I. Pastan,et al. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. , 1998, Cancer research.
[14] C. D. Salcido,et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. , 2010, Journal of the National Cancer Institute.
[15] Jean-François Ethier,et al. Reproductive Biology and Endocrinology Open Access Animal Models of Ovarian Cancer , 2022 .
[16] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[17] Gabriel S. Eichler,et al. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database , 2009, Molecular Cancer Therapeutics.
[18] Jean-Pierre Gillet,et al. Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.
[19] Brendan Borrell,et al. How accurate are cancer cell lines? , 2010, Nature.
[20] T. Efferth,et al. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. , 2007, Biochimica et biophysica acta.
[21] F. Murray-Zmijewski,et al. A complex barcode underlies the heterogeneous response of p53 to stress , 2008, Nature Reviews Molecular Cell Biology.
[22] M. Gottesman,et al. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. , 2003, Cancer research.
[23] C. Wolf,et al. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient , 1987, International journal of cancer.
[24] John Quackenbush. Microarray analysis and tumor classification. , 2006, The New England journal of medicine.
[25] Susan G Hilsenbeck,et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.
[26] D. Green,et al. Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.
[27] B. Vanderhyden,et al. Models of ovarian cancer—Are we there yet? , 2005, Molecular and Cellular Endocrinology.
[28] Richard Simon,et al. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. , 2008, European journal of cancer.
[29] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[30] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[31] F. Lee,et al. Apoptotic pathways of epothilone BMS 310705. , 2003, Gynecologic oncology.
[32] T. Langmann,et al. Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. , 2006, Clinical chemistry.
[33] D. Haber,et al. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.
[34] F. de Longueville,et al. DualChip® microarray as a new tool in cancer research , 2006, Expert review of molecular diagnostics.
[35] T. Barrette,et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. , 2007, Neoplasia.
[36] John N Weinstein,et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.
[37] M. Gottesman,et al. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. , 2011, Current pharmaceutical biotechnology.
[38] Robert C. Bast,et al. The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.
[39] F. Lee,et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[41] S. Cannistra,et al. Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.
[42] F. de Longueville,et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia , 2006, Molecular Cancer Therapeutics.
[43] H. Parkinson,et al. A global map of human gene expression , 2010, Nature Biotechnology.
[44] J. Mesirov,et al. Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Chuang,et al. Transcriptional Regulation by p53 , 1995, The Journal of Biological Chemistry.